Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Nektar eczema candidate 'checked all of the boxes' in long-term phase 2 data
(7h)
Evommune’s Dupixent-like phase 2 eczema data drive 75% stock rally
(8h)
AstraZeneca reveals oral GLP-1 scored phase 2 wins but holds back weight loss data
(8h)
Merck teams up with British medtech to boost vaginal therapeutics delivery system
(11h)
AstraZeneca relaxed about relaxin drug's poor efficacy in phase 2 heart failure trial
(13h)
Kailera, Hengrui tout up to 12% weight loss in midstage study for obesity pill
(23h)
OrsoBio hits target in midstage study for metabolic conditions but stays silent on details
(1d)
FDA rejects Regenxbio's gene therapy in Hunter syndrome, leaving CEO 'concerned'
(1d)
Bristol Myers and Evinova pen global development partnership
(1d)
Lilly buys Orna in $2.4B deal to enter in vivo CAR-T arena
(1d)
BioPharma Dive
Novo combination obesity shot meets goal in diabetes trial
(1w)
Sanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials
(1w)
GSK walks away from pioneering Wave RNA editing drug
(1w)
Building a robust in-process testing plan for cell therapy manufacturing success
(1w)
Amgen gives up on its once-prized eczema drug
(2w)
AstraZeneca leans into obesity, striking wide-ranging alliance with China’s CSPC
(2w)
Politicization runs deeper than ever at FDA, risking long-term impacts
(2w)
The biopharma industry outlook on 2026: Optimism and tension
(2w)
Sanofi expects vaccine sales growth to dip amid ‘challenging environment’
(2w)
AstraZeneca strengthens China ties with planned $15B investment
(2w)
Endpoints News
Isomorphic claims major advance with new AI drug design engine
(2h)
ILiAD raises $115M round to advance whooping cough vaccine
(2h)
AbbVie, AstraZeneca lose appeal in Louisiana 340B contract pharmacy fight
(2h)
NIH stops low-dose Xarelto arm of large stroke study due to safety concerns
(3h)
Is AstraZeneca on track to meet its $80B revenue target?
(6h)
The fallout from Novo vs. Hims
(6h)
Shanghai's Cascade gets $72M to pursue MASH, obesity and diabetes drugs
(7h)
Nektar posts one-year eczema success; Pfizer ends malnutrition trial
(7h)
CSL’s Paul McKenzie out, as Gordon Naylor named interim CEO
(10h)
AstraZeneca’s obesity pill hits in Phase 2, key cancer trials pushed back
(10h)
BioSpace
Webinar: 2026 Hiring Trends and Job Market Signals
(1h)
Evommune Soars as Dermatitis Treatment Rivals Dupixent in Mid-Stage Trial
(7h)
Hims & Hers’ Woes Compound as FDA Hits Company With Warning Letter
(9h)
Kailera, Hengrui Push Oral GLP-1/GIP Pill to Phase 3 After Clearing Mid-Stage China Study
(9h)
REGENXBIO’s Hunter Syndrome Gene Therapy Fails to Win FDA Nod
(10h)
AstraZeneca Teases ‘Very Competitive’ Weight-Loss Pill—But Stays Mum on Details
(10h)
HER2’s Digital Rebirth Is Unlocking the Full Potential of ADCs
(14h)
Facing Talent Crunch, Radiopharma Field Casts a Wide Net
(17h)
Eli Lilly Enters CAR T Realm With $2.4B Orna Buy, Starting With Autoimmune
(1d)
Biogen’s Much Anticipated Tau Readout in Alzheimer’s Will Spur More Questions
(1d)
STAT News
We tested the government’s official new AI nutrition tool: Grok
(1h)
Landmark settlement could create new protections for harm reduction under disability law
(3h)
Abridge CTO on Epic and what’s after AI scribing
(3h)
TrumpRx: Hype or real savings?
(7h)
Evommune reports positive mid-stage data for eczema drug
(8h)
Trump administration revives effort to launch pilot initiative reworking drug discount program
(8h)
We’re reading about FDA rejecting a rare disease drug, a warning to a Hims compounding pharmacy and more
(8h)
Trump cabinet members watching their diets with RFK Jr.
(8h)
Eczema drug from Nektar Therapeutics maintains skin responses in one-year study
(10h)
Did the AMA change its position on surgery for transgender minors?
(13h)
BioPharma Trend
Isomorphic Labs Presents an AI Drug Design Engine That Goes Beyond AlphaFold 3
(2h)
Takeda Signs $1.7B AI-Enabled Small Molecule Discovery Deal with Iambic
(1d)
Flagship’s Generate Biomedicines Eyes IPO Amid Reopening Biotech Market Window
(5d)
Anthropic, HHMI, and Allen Institute Launch Claude-Integrated AI Collaborations for Life Science Research
(6d)
Phylo, an Agentic AI Lab, Launches with $13.5M Seed Round, Introduces Biomni Lab
(6d)
Inductive Bio Wins OpenADMET Blind Challenge With Machine Learning Models
(1w)
Beyond GLP-1: A New Combination Strategy Shows Up to 31.3% in Preclinical Study
(1w)
How Digital Health Technologies are Reshaping Clinical Development
(1w)
This AI Ready Single Molecule Proteomics $1.6M Grant Targets Parkinson’s Alpha Synuclein
(2w)
Eli Lilly Strikes Up to $1.1B Gene Editing Deal with German Startup
(2w)
Drug Channels
Copay Accumulators and Maximizers in 2025: Popular, Profitable, and Problematic
(11h)
In an Uncertain 340B Environment, Kalderos Offers a Clear Path Forward
(4d)
The FTC Blows Up Express Scripts’ PBM Model—and Launches the Net Pricing Drug Channel
(6d)
Latest CMS Data Reveal Six Trends Reshaping U.S. Drug Spending
(1w)
From Cost Center to Insights Center: How Patient Support Will Go Beyond the Call in 2026
(2w)
Drug Channels News Roundup, January 2026: Cuban vs. Optum, McKesson’s Biosimilar Play, States vs. Accumulators, 340B Windfalls, and Ozempic Ads
(2w)
New Drug Launches in a Self-Pay World: Why Access Strategy Matters as Much as Innovation
(3w)
The Big Three PBMs’ 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs
(3w)
The Net Pricing Revolution in the Drug Channel: What’s Deflating the Gross-to-Net Bubble
(4w)
NEW: The Drug Channels 2026 Video Webinar Series
(1mo)
European Biotechnology Magazine
This Memo sticks: CSL bites in Switzerland for antibody collaboration
(6h)
This Memo sticks: CSL bites in Switzerland for antibody collaboration
(7h)
4Moving Biotech raises €12m to prove whether GLP-1 can crack osteoarthritis
(8h)
Bayer: at least success with coagulation factor XIa in phase 3 of stroke trial
(14h)
Dublin-based Aerska secures $39M Series A to push RNA medicines into the brain
(1d)
U.K. life sciences infrastructure gets a boost as London and Cambridge expand
(1d)
SciVario® twin: One Controller for All Your Needs
(1d)
BioArctic is cashing in on Eisai and Biogen growing sales in Alzheimer’s disease
(4d)
Agomab goes public on Nasdaq as biotech IPOs top $1bn in a single week
(4d)
Novartis celebrates strong profits, while the CEO enjoys record pay triggering discussion
(4d)
Drug Hunter
vimseltinib
(5h)
The New WIZ-kid in Protein Degradation
(1d)
Module 1 Quiz
(1d)
Identification Methods for Drug Repurposing: Case Studies in Neurodegeneration
(4d)
bezuclastinib (CGT9486)
(5d)
Kygevvi
(6d)
ENPP1 Inhibitors: Will Taking the Brakes off STING Help Turn up the Heat on “Cold” Tumors?
(1w)
It Takes Multiple to Mambo
(1w)
Section 4: The All-Important Dose
(1w)
lanifibranor (IVA-337)
(2w)
Labiotech.EU
Astellas’ “strategic brands” and “primary focuses” after XTANDI
(8h)
Breast cancer treatments heat up: Six therapies poised to transform patient outcomes
(1d)
Top biotech deals in January 2026
(4d)
How Eli Lilly’s biotech collaboration model is rewriting early-stage innovation
(4d)
The biggest biotech funding rounds in January 2026
(6d)
Nine biotech companies that could revolutionize obesity treatments
(1w)
Amarin v. Hikma: settling the skinny label question
(1w)
Johnson & Johnson’s pipeline strategy: What does 2026 have in store for the big pharma?
(2w)
Building a smart oncology pipeline with Cumulus Oncology
(2w)
U.K. biotech ends on a high note in 2025 despite plummeting investments, report reveals
(2w)
Bio IT World
Trends from the Trenches: What Lies Ahead in Bioinvestment
(16h)
The Role of the Statistical Programmer is Evolving: Here’s How It’s Changing and What That Means for Pharmaceutical Companies
(4d)
PacBio Sells Their Short-Read IP to Illumina
(1w)
Unlocking the Dangers of Disrupted Sleep
(1w)
Eli Lilly Gears Up for a Busy Year with a Diversified Pipeline
(2w)
Follow the Money: Helicon Peptide Development, Next-Gen Obesity Metabolic Disease Therapies, Cell Stress Sensing Platform
(2w)
BigHat, Revvity Collaborate with Eli Lilly, Immunai Signs Agreement with Bristol Myers Squibb, SandboxAQ Launches New AI Model
(2w)
Dealmakers Predict Banner Year as Biopharma M&A Momentum Builds
(3w)
Improved Drug Safety Needs Better Data Before AI
(3w)
AI in Pharma: Progress Made, But Data Challenges Persist
(3w)
GEN News
ALS and Dementia Linked to Bacterial Sugar via Gut–Brain Axis
(1h)
How Long COVID-Related Brain Changes May Link to Alzheimer’s Disease
(1h)
Gator Bio and Hudson Lab Display Antibody Discovery Automation Solution at SLAS
(2h)
Data-Driven Strategies for Addressing Bispecific Antibody Purification Challenges
(3h)
Opentrons Uses Nvidia Tech to Build Training Data That Powers Physical AI in the Lab
(1d)
How the Flu Causes an Achy Breaky Heart
(1d)
Chimeric Small Molecule Drug Conjugate Effectively Targets Solid Tumors
(1d)
Physiological Human In Vitro Models to Study and Evaluate Tumor Immunology
(1d)
Antibiotic Resistant Genetic Elements Inactivated by CRISPR-Based Tool
(1d)
Previously Unknown Gut Bacteria Emerge as Global Marker of Health
(1d)
Cure Today
Keytruda Combo Approved for Platinum-Resistant Ovarian Cancer
(1h)
From Missed Signs to Second Chances After a Liver Cancer Diagnosis
(1h)
Chris Draft Shares Steps to Help Patients Regain Control After Cancer
(2h)
Seeking a Dose of Hope Amidst Cancer
(4h)
FDA Fast Track Designation Highlights New Option in Advanced Liver Cancer
(6h)
FDA Clears Phase 2b Study of Teverelix in Advanced Prostate Cancer
(7h)
When Cancer Care Becomes a Logistical Balancing Act
(8h)
Mom of Four Shares Story of Her Breast Cancer Diagnosis
(1d)
Cancer Anniversaries Good and Bad
(1d)
A Liver Cancer Journey Marked by Persistence, Family and Hope
(1d)
Contract Pharma
Waters Completes Combination With BD Biosciences, Diagnostic Solutions Businesses
(1d)
Bruker Introduces Label-Free Characterization Platform for Nanoscale Bioparticles
(1d)
Innovent and Lilly’s Seventh Collaboration Sets Model to Accelerate Pipeline Development
(1d)
PharmaEssentia to Establish a Manufacturing Subsidiary in Puerto Rico
(1d)
Fresenius Kabi, Phlow Partner to Onshore the Manufacture of Epinephrine Injection in the U.S.
(1d)
Eurofins Viracor BioPharma Services Expands Service Portfolio
(1d)
Samsung Biologics Product Carbon Footprint System Validated by Third Party
(4d)
Proven Expertise and Customized End-to-End Solutions for Your Products
(4d)
Lilly 4Q Results
(4d)
Eisai, Henlius Strike Japan Commercialization Deal for PD‑1 Antibody Serplulimab
(4d)
Pharma Times
AstraZeneca bladder cancer therapy wins NICE backing
(12h)
Head masters
(12h)
Strong clinical data for Breye lead asset danegaptide
(1d)
EHP Awards triumph
(1d)
Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
(1w)
IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
(1w)
En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
(1w)
ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
(1w)
CERo reports encouraging early data from phase 1 trial of CER‑1236
(2w)
ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
(2w)
Medcity News
Evommune Starts Making Case to Challenge Dominance of Sanofi’s Dupixent in Atopic Dermatitis
(1h)
Lilly’s Chief Information & Digital Officer: AI Use Goes Far Beyond Just Drug Discovery
(2h)
Solace Health Reaches Unicorn Status by Taking the ‘Homework’ Out of Care Navigation
(3h)
From Pandemic Urgency to Practical Impact: How Diagnostics Investment Priorities Are Evolving
(8h)
Top ATP Tests for Effective Sanitation and Hygiene Monitoring
(8h)
The Next Stage in At-Home Healthcare is Arriving
(8h)
Take Control of Your Healthcare News: Add MedCity News to Your Google Preferred Sources
(9h)
NYU Langone Taps Isaac Health for New Virtual Dementia Care Model
(1d)
Eli Lilly Expands Its In Vivo Ambitions, Acquiring Cell Therapy Startup Orna for up to $2.4B
(1d)
The Best EAP Providers in America: Top 10 Services for Workplace Support
(1d)
Chemical & Engineering News
EPA reapproves dicamba use, despite MAHA opposition and previous court bans
(4h)
Feb. 10 Business Watch: Biotech IPOs are back; FMC may soon be for sale
(4h)
Obituary: Lal Vishwakarma
(7h)
Obituary: Lal Vishwakarma
(7h)
Royal Society of Chemistry awards Carolyn Bertozzi Honorary Fellowship
(8h)
Chemistry in Pictures: Holey unsinkable
(8h)
Decarbonizing with a box of hot bricks
(1d)
CAS launches CAS Intelligence Hub
(1d)
Quiz: C&EN’s periodic table challenge
(1d)
Obituary: Dwain M. White
(1d)
The Pharma Letter
Kailera and Hengrui report ribupatide delivers 12.1% weight loss at 26 weeks
(5h)
Novo Nordisk commences legal action against Hims & Hers
(5h)
AstraZeneca’s Imfinzi wins NICE nod as first perioperative IO treatment for MIBC
(6h)
ICER releases evidence report on therapies for IgA nephropathy
(6h)
FDA accepts Takeda’s oveporexton NDA for priority review
(7h)
Moderna inks long-term deal with Mexican govt
(7h)
Gyala launches first-in-class CD84 CAR-T trial in acute leukemias
(7h)
Russia faces shortage of schizophrenia drug Latuda
(8h)
Sanofi Ventures co-leads $85 million QuantX series B
(9h)
Kainova round supports clinical advancement of GPCR-targeting therapies
(10h)
Targeted Oncology
Analysis Reveals Survival Gap, Racial Disparities in Ovarian Cancer Research
(5d)
Addressing the Overlooked: A New Approach to Treatment-Related High-Risk MDS
(5d)
Balancing Efficacy and Toxicity of Oral SERDs in Breast Cancer
(6d)
FDA Expands Approval of Aptima HPV Assay for Cervical Cancer Primary Screening
(6d)
MDT Boosts Survival Outcomes in Oligometastatic Prostate Cancer
(6d)
Pelareorep Earns FDA Fast Track for Second-Line KRAS-Mutant Metastatic CRC
(6d)
ADCs Could Move Up the Treatment Line in GI Cancers
(6d)
Beyond Chemo: Dr Ana Garrido-Castro on the Evolving TNBC Landscape
(6d)
Progress and Gaps in Lung Cancer Biomarker Testing at Community Centers
(6d)
Navigating the Future of CLL Care
(6d)
MedWatch
Former FDA chief backs Novo Nordic against Hims & Hers: They've crossed the line
(8h)
AstraZeneca expects robust 2026, led by strong cancer drug demand
(10h)
BII expands beyond Denmark: Launches units in UK and Italy
(11h)
Indian drugmakers ready to pounce as Novo Nordisk's patent expiry looms
(13h)
Novo Nordisk working on response after FDA letter about misleading Wegovy ad
(13h)
Trump's new medicine platform starts with just a few drugs
(13h)
Coloplast CFO looks forward to welcoming new boss in the spring
(14h)
Gubra launches new business unit
(14h)
Hims & Hers calls Novo Nordisk's lawsuit a Danish attack on millions of Americans
(15h)
Eli Lilly acquires biotech company for billions
(15h)
In The Pipeline
Gumming Things Up On Purpose
(1h)
Crystals Where There Were None
(5d)
What the Literature is Filling Up With
(6d)
A Complex Cancer-Alzheimer's Connection
(7d)
The 2025 FDA Approvals
(1w)
A New LLM System for Synthesis Planning
(2w)
Rev Up The Viral Factories!
(2w)
Add Up Those Energies
(2w)
The Disastrous US Vaccine Landscape
(2w)
Microstructures All Around
(3w)
Pharmaphorum
FDA kicks off review of Takeda's narcolepsy hopeful
(6h)
Kailera stakes a claim to the oral weight loss category
(8h)
Kailera, Hengrui stake claim to oral weight loss category
(8h)
AstraZeneca raises guidance on stellar cancer drugs growth
(9h)
Takeda signs $1.7bn AI alliance with Iambic
(10h)
Dismay as FDA blocks Regenxbio's Hunter syndrome therapy
(11h)
Lupin settles Myrbetriq patent spat with Astellas for $90m
(12h)
Lilly strikes again, buying CAR-T firm Orna for $2.4bn
(1d)
Data builds on Roche's dominance in primary progressive MS
(1d)
Novartis breaks ground on San Diego biomedical R&D site
(1d)
Drug Discovery Weekly
Charles River and Synthace to advance assay development
(5h)
Emulate showcases organ-chip platform at SLAS2026
(6h)
SLAS2026: Day One Round-Up
(9h)
DDW Highlights: 10 February 2026
(10h)
Collaboration to advance drug enhancing immunotherapy response
(10h)
Kainova secures funding to develop GPCR-targeting therapies
(11h)
US Senate reauthorises Priority Review Voucher scheme
(12h)
Global research launched into early diabetic kidney disease
(1d)
This week in Drug Discovery (2 – 6 February)
(4d)
ALTx Therapeutics launched to develop novel cancer treatments
(4d)
HIT Consultant
Solace Health Raises $130M to Expand Patient Advocacy Network
(1h)
Garner Health Secures $118M to Reward Top Doctors
(1h)
Midstream Health Partners with CommonSpirit Health to Deploy AI Financial Operations Platform
(7h)
Canary Speech Partners with Intermountain Health to Study Vocal Biomarkers for Multiple Sclerosis
(8h)
The “Agent” Dilemma: How Blockchain Could Save Patient Privacy in a $500B AI Market
(8h)
The Rise of AI Triage: Navigating Regulatory Challenges and Patient Care Workflows
(15h)
Mount Sinai Study: LLMs Susceptible to Medical Misinformation in Clinical Notes
(20h)
KLAS: Why Ambulatory Practices Are Ditching Point Solutions for Epic and athenahealth
(1d)
athenahealth and b.well Launch QR-Code Intake to End Paper Forms
(1d)
How Agentic AI Optimizes HCP Marketing and ROI in Life Sciences
(1d)
Insights: Pink Sheet
Sobi Takes Second Shot At EU Gamifant Approval
(2h)
Potential Blockbusters From AstraZeneca And Lilly Now Under EMA Review
(2h)
GLP-1s Likely TrumpRx Savings Focus Over Old, Genericized Products
(4h)
EMA Backs Smarter Tool To Spot Pregnancy‑Related Medicine Risks
(8h)
Pharma Hit With $755m In False Claims Act Recoveries
(1d)
US FDA Compassionate Use Reviews ‘Not Affected’ By Trump Policies
(1d)
US FDA Flags Launch Ad For Novo Nordisk’s Wegovy Pill; Is Super Bowl Commercial Next?
(1d)
EU CHMP Opinions And MAA Updates
(1d)
EU AI Act Could ‘Set Back’ Benefits Of AI In Drug Development If Applied To RD
(1d)
US-India Trade Deal : Generics Dance Goes On, Oil Prices To Be Watched
(3d)
BioXconomy
Experts unveil AI breakthroughs in streamlining regulatory reviews
(5h)
Capsida confirms cause of death in clinical trial fatality for rare genetic disorder
(9h)
Lilly to buy Orna in CAR T deal worth up to $2.4bn
(10h)
Viatris, Septerna, BIO, Takeda name new legal chiefs
(10h)
Generate Biomedicines targets IPO to advance asthma treatment
(13h)
Pharmaceutical companies require robust internal audit systems to prepare for FDA inspections
(1d)
From isolation to integration: Redefining ethics and compliance in the data-driven era
(1d)
Medable launches AI agent to help with trial outcome assessment
(1d)
UAE partners with Colossal Biosciences to lead global conservation efforts
(1d)
Dual-targeting siRNAs could treat more complex genetic diseases
(4d)
BioCentury
Start-up funding, the perils of compounding, and neuropsych insights — a BioCentury podcast
(21h)
Galux: Scaling AI-designed biologics
(22h)
The next wave of biotech growth — a Perspective
(1d)
Lilly buys Orna, strikes broad pipeline deal with Innovent: Deals Report
(1d)
McKinsey vet Franck Le Deu joins Nisa Leung’s new fund; plus C-suite shuffle at Bicycle
(3d)
Series A companies: Biotech’s class of 2025
(3d)
Compounded Wegovy is more than a scam — it threatens innovation
(4d)
Eikon, Agomab raise $350M total in IPOs, sink in aftermarket: Public Equity Report
(4d)
Sanofi misses in Fabry: Is it time to move on from GCS inhibition in the indication?
(4d)
Latent Labs: AI-designed, ready-to-develop biologics
(4d)
SCRIP
Evommune’s Atopic Dermatitis Data Competitive With Dupixent
(31m)
CSL CEO Paul McKenzie Exits With Former Exec Gordon Naylor Stepping In
(4h)
FDA Delivers Regenxbio Another Blow, This Time for RGX-121
(4h)
Aerska Builds Cashpile To Advance Brain Shuttle Tech
(6h)
Sustained By Cancer Success, AstraZeneca Is Still Sizing Up Obesity Opportunity
(7h)
gMyrbetriq: Lupin Settles With Astellas, Zydus Says Court Has Directed Mediation
(13h)
gMyrbetriq: Lupin Settles With Astellas, Zydus Says Court Directed Mirabegron Mediation
(13h)
Stock Watch: Pfizer Navigates Vaccine Gains And Acquisition Pains
(13h)
TrumpRx May Be New, But It Showcases Pharma’s Age
(1d)
Insmed Plots Its Course For A Long Growth Journey
(1d)